



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/04	A1	(11) International Publication Number: WO 98/23296
		(43) International Publication Date: 4 June 1998 (04.06.98)
<p>(21) International Application Number: PCT/GB97/03205</p> <p>(22) International Filing Date: 21 November 1997 (21.11.97)</p> <p>(30) Priority Data: 9624612.9 26 November 1996 (26.11.96) GB</p> <p>(71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 1-2, N-0401 Oslo (NO).</p> <p>(71) Applicant (for GB only): COCKBAIN, Julian [GB/GB]; 27 Ladbroke Road, London W11 3PD (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): MALTHE-SØRENSEN, Dick [NO/NO]; Nycomed Imaging AS, Nycoveien 1-2, N-0401 Oslo (NO). SCHELVER HYN, Anne, Cathrine [NO/NO]; Nycomed Imaging AS, Nycoveien 1-2, N-0401 Oslo (NO). AABYE, Arne [NO/NO]; Nycomed Imaging AS, Nycoveien 1-2, N-0401 Oslo (NO). BJØRSVIK, Hans, René [NO/NO]; Nycomed Imaging AS, Nycoveien 1-2, N-0401 Oslo (NO). BREKKE, Geir [NO/NO]; Nycomed Imaging AS, Nycoveien 1-2, N-0401 Oslo (NO). SJØGREN, Carl, Einar [NO/NO]; Nycomed Imaging AS, Nycoveien 1-2, N-0401 Oslo (NO).</p>		<p>(74) Agents: COCKBAIN, Julian et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
(54) Title: PROCESS FOR THE PRODUCTION OF IODINATED ORGANIC X-RAY CONTRAST AGENTS		
<p>(57) Abstract</p> <p>The present invention provides a process for the production of an organic iodinated X-ray contrast agent, characterized in that process control comprises vibrational (e.g. infrared, Raman or preferably near-infrared) spectroscopic monitoring of the reaction mixture in at least one of the process steps, preferably one of the final reaction steps.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS FOR THE PRODUCTION OF IODINATED ORGANIC
X-RAY CONTRAST AGENTS

This invention relates to improvements in and relating to the manufacture of iodinated organic X-ray contrast agents.

For many years, the X-ray contrast media market has been dominated by the inorganic barium compounds used for imaging the gastrointestinal tract and the parenterally-administered organic iodinated compounds used for imaging elsewhere, in particular the circulatory system. These iodinated compounds, such as iohexol, iopentol, iodixanol, ioversol, iopamidol, ioxaglate, metrizoate, metrizamide, etc., are manufactured and sold as pharmaceuticals and as with the commercial manufacture of any pharmaceutical compound it is important to optimize their efficiency of manufacture (eg. to maximize yield and purity while minimizing demand on equipment, materials and time).

As pharmaceuticals however, the manufacture of iodinated X-ray contrast agents is dominated by the requirement for product purity and accordingly most process steps are monitored using the "gold standard" of HPLC which gives a clear and unmistakeable indication of the presence and likely identity of by-products and residual reagents in any reaction mixture.

HPLC however is a relatively slow technique taking perhaps several hours from sampling to completion of data analysis and offers little freedom to the process operators for real-time feedback control of process performance.

The present inventors have now realised that more rapid, and indeed on-line monitoring, of the processes for the production of iodinated X-ray contrast agents can surprisingly be achieved using vibrational (eg. near infrared (NIR), infrared or Raman) spectroscopy. Such an on-line monitoring system allows a more rapid response in process control, eg. in terms of changing process conditions such as temperature, pressure and pH, controlling addition of reagents, or terminating reactions at the optimal point. That such spectroscopic techniques can be used for this purpose is doubly surprising. Firstly, it is surprising that a spectrum of a complex reaction mixture can be used as such to reliably predict the amount of single species, without first requiring the use of separation techniques such as chromatography, even when product purity is of paramount concern such as is the case with drug substances. Secondly, vibrational spectrometry has for many years been viewed as an academic tool, with little or no relevance for process monitoring and complex reaction mixtures. Contrary to what was believed, it is now surprisingly found that vibrational spectroscopic techniques (eg. infrared and NIR spectrometry) are applicable even to reaction mixtures with high aqueous contents. With Raman spectroscopy, high water contents of the solvent are not problematic. Raman spectrometry, moreover, is particularly sensitive to detection of molecular species with large numbers of polarisable electrons, such as iodinated X-ray contrast agents.

NIR spectroscopy has previously been used for monitoring of hydrocarbons (see for example WO 91/15762, US-A-4963745, DD-272129 and WO 89/06244) but has not previously been suggested as being suitable for monitoring production of contrast agents, especially X-ray and MRI contrast agents.

Thus viewed from one aspect, the present invention provides a process for the production of an organic iodinated X-ray contrast agent, characterized in that process control comprises vibrational (eg. infrared, Raman or preferably near-infrared) spectroscopic monitoring of the reaction mixture in at least one of the process steps, preferably one of the final reaction steps.

Monitoring using vibrational spectroscopic techniques according to the invention will typically involve deriving characteristic data values from the detected spectra, comparison of such characteristic values with calibration data and modification of process parameters based on the outcome of the comparison. All these steps may, and preferably will, be automated with the process of the invention being operated under computer control.

The manufacturing of contrast agents, eg. organic iodinated X-ray contrast agents, includes production of the chemical drug substance (the "primary production"), followed by formulation to the drug product (the "secondary production"). The drug substance is usually made and purified in a multi-step chemical synthesis and the monitoring according to the invention may take place in one, some or all of these multiple steps, and particularly conveniently comprises monitoring of the reactor contents in at least one, and preferably two to six, of the final reaction steps. For the purposes of the present invention a reaction step is defined as a process which involves converting one isolatable and purifiable compound into another or the transformation of a compound from one form to another (eg. a precipitation or crystallization or a phase change or the formation of an amorphous form of a product) and/or an essentially mechanical step such as the cleaning of equipment. Such compounds will either be reagents (starting materials not manufactured by the process

operator), intermediates, or the final drug substance.

The vibrational spectra of crystalline iodinated organic X-ray contrast agents are usually sufficiently different from those of the corresponding amorphous materials or indeed from those of the same agents in different crystalline forms as to allow unambiguous identification of the crystalline form being monitored. Raman spectra show the same level of detail as infrared spectra with respect to band shifts and splittings caused by different solid (polymorphic) forms of a substance, but Raman spectrometers are more conveniently coupled on-line, eg. to a reaction vessel in which an iodinated X-ray contrast agent is precipitated from a solution. The grain size of the resulting solid will also affect the appearance of the infrared, NIR and Raman spectra, so that other physical characteristics of the solid could also be inferred from the spectra.

In one embodiment, the present invention therefore involves a process for the production of an iodinated X-ray contrast agent, involving an on-line quantitative monitoring of physical characteristics (eg. crystal size, crystal type, etc.) of the desired product. This monitoring may be done on-line during precipitation of the solid substance, by multivariate calibration and/or classification and Raman spectrometry coupled to the reaction vessel by means of optical fibres and a suitable optical window through which the exciting laser light is transmitted and the resulting Raman scattering is collected and transmitted back to the spectrometer. Alternatively, commercially available infrared waveguides and optical windows may be used to connect an infrared (FT-IR) spectrometer to the reaction vessel, or a NIR spectrometer may be connected using optical fibres, and the spectral data may be collected and the physical characteristics of the precipitate may be predicted from a suitable multivariate calibration and/

or classification model, eg. based on reference spectra of pure polymorphs or mixtures thereof.

In the process of the invention, vibrational spectroscopic data (eg. NIR spectroscopic data) are collected for the reaction mixture, either by in-situ measurement, on-line sampling (eg. drawing off a sample through a line delivering the sample to the spectroscopic apparatus) or off-line sampling (eg. drawing off of a discrete sample and placing some or all of that sample in the spectroscopic apparatus). The sample monitored may thus be in or taken from a reaction vessel or a duct connecting reaction vessels. All of these data collection steps may be effected automatically, eg. under computer control; however of these, in situ measurement and on-line sampling are preferred since the delay before spectroscopic measurement can be minimized.

The spectroscopic data generated is conveniently subject to an automated calculation procedure, eg. based on a previously established multivariate calibration, allowing almost instantaneous feedback to the process control system (which will conveniently be computer controlled). Thus spectroscopic analysis gives the possibility to make adjustments to process parameters or to take actions (eg. addition of reagents, termination of reaction etc.) almost instantly so as to maintain or achieve optimal selectivity in the synthesis.

The calibration referred to above will conveniently be done with reference to a high accuracy analysis system appropriate to the system and property under investigation, eg. HPLC or TLC. Thus a synthetic or other process step may be run with samples being taken repeatedly throughout the progress of the reaction, and those samples being subject to both spectroscopic (eg. NIR) and HPLC analysis. Multivariate analysis of the


vibrational (eg. NIR) spectra may then be performed to identify the spectral status that corresponds uniquely to the HPLC results for the optimum stage at which to effect a process change (eg. addition of further reagent, termination of reaction, change to different pH, temperature or pressure, etc.) and similarly the effects of undesired process changes (eg. incorrect pH, temperature or pressure, or inadequate or excess reagent) on the spectrum may be determined so that, where these effects are detected, the appropriate corrective action may be taken. In other words, from a set of calibration samples analysed by both the selected vibrational spectroscopic technique used in the process of the invention (eg. NIR) and the reference method (eg. HPLC) a calibration model may be constructed from which the characteristics of unknown samples can be predicted. In subsequent operation of the process of the invention the results from spectroscopic analysis are obtained within seconds and appropriate action to adjust reaction conditions (eg. to stop conversion of product to by-product or to terminate the reaction at the most efficient point) may be taken with less delay than is possible using the conventional chromatographic methods.

Multivariate analysis of spectra to generate the calibration model may be performed using conventional techniques, eg. as discussed in "Multivariate Calibration" by Martens and Næs, John Wiley & Sons, 1991.

While the invention is primarily concerned with preparation of organic iodinated X-ray contrast agents, and in particular non-ionic X-ray contrast agents (eg. iohexol, iopentol, iodixanol, iopamidol and ioversol), it is also applicable to organic contrast agents as a whole and particularly to process steps in which the reaction mixture is slightly aqueous (eg. up to 5%, especially up to 2% and more particularly up to 1% by

weight) either due to inclusion of water in the starting materials or due to generation of water during the reaction. When Raman spectroscopy is used, the reaction mixtures may even be significantly more aqueous, eg. liquid phases may contain up to 50% or even 70% by weight water, for example in cases where water is present as a solvent or co-solvent or where it is added as a non-solvent (for example to precipitate out a dissolved compound). In on-line monitoring of rinse water, etc, as is described in Example 2 below, the water content of the system under study may be still higher.

X-ray contrast agents and intermediates in the syntheses of such agents are often polyiodinated aromatic amides with several hydroxylic groups attached. The intermediates, some of which lack iodine substituents, frequently possess primary, secondary or tertiary amino groups. The process of the invention will however be described by way of example with reference to the production of iodixanol (1,3-bis(acetamido)-N,N'-bis[3,5-bis(2,3-dihydroxypropylaminocarbonyl)-2,4,6-triiodophenyl]-2-hydroxypropane). This contrast agent has the following chemical structure:



The process step monitored using the process of the invention will generally take place in the gas phase or in the liquid phase. Particularly conveniently it will involve a liquid phase containing a solvent or solvent mixture and optionally anti-solvents. The solvent, co-solvents or anti-solvents may be any material capable of

functioning as solvents or anti-solvents, but preferably will be materials with as few peaks as possible in the spectra being studied close to or overlapping with the peaks of the compounds of interest. Examples include water, aliphatic hydrocarbons, aromatic hydrocarbons, halogenated hydrocarbons, alcohols, polyols, ketones, esters, ethers, nitriles, DMSO, DMF, etc., eg. water, C₁₋₄ alkanols, C₂₋₆ alkoxyalkanols, C₂₋₆ linear or cyclic ethers, C₃₋₆ ketones, C₂₋₆ esters, C₄₋₁₀ hydrocarbons, C₁₋₄ haloalkanes, etc.

As mentioned above, the manufacturing processes of the contrast agents usually constitute several chemical transformations, with a number of intermediates involved. Vibrational spectra (eg. near infrared spectra) of mixtures of contrast agents and/or their intermediates can easily be collected by a spectrophotometer (eg. a near infrared spectrophotometer) and a probe connected to the instrument by one or more optical fibres. For calibration, several scans should be collected of each sample, and the reaction solvent may appropriately be used as a reference.

The building of the calibration model from the calibration sample set can easily be performed by techniques known to those skilled in the art. Standard methods for a multivariate calibration may be applied. The parameters of interest must be determined by a reference method during the building of the calibration method. The accuracy of the predicted values from the calibration model thus cannot be better than what is obtained with the reference method of analysis.

Once the calibration model is built up, an unknown sample can be measured by the appropriate spectrophotometer, and the resulting spectrum can be correlated with the calibration data. A calculation of predicted values of the parameters of interest can be

performed by a computer within a few seconds, and the analytical results can be printed out or displayed on a computer screen, or it may if desired be fed directly into a control algorithm, which in turn initializes the correct action in the regulation of the process.

The invention will now be illustrated by reference to the following non-limiting Examples and the accompanying drawings, in which:

Figure 1 is a plot of an NIR spectrum for a reaction mixture in the synthesis of iodixanol;

Figure 2 is a plot of the NIR spectrum of Figure 1 following pre-treatment;

Figure 3 is a plot of the spectral weighting for a calibration model;

Figure 4 is a plot comparing values indicative of the degree of overalkylation as measured and as predicted using the calibration model of Figure 3; and

Figure 5 is a plot comparing values indicative of the degree of overalkylation as measured and as predicted using a further calibration model.

EXAMPLE 1

Synthesis of iodixanol from 5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophtalamide

All experiments were carried out in a 1 L jacketed glass reactor equipped with a stirrer and a water bath. NIR transfectance spectra were collected with a Quantum 1200 Plus NIR analyzer (LT Industries Inc.) in the spectral region from 1200 nm to 2400 nm with fibre optics and a Bubble Shedding probe with a pathlength of

- 10 -

2 mm. 90 scans were collected for each spectrum, and air was used as the background. Two spectra were collected of each sample. HPLC (reversed phase, water/acetonitrile) was used as the reference method, with one or three parallels of each sample.

The following procedure was used in all the three experiments: 2-methoxyethanol (300 ml) and sodium hydroxide (20 g) was added to the reactor at 50°C, and 5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophthalamide (304 g) was added after two hours of stirring. All solids were allowed to dissolve overnight before cooling to 30°C and adjustment to pH 12 with diluted hydrochloric acid. Epichlorohydrin (11 g) was added to the solution after further cooling to 15°C, and the reaction was allowed to proceed for 51 hours. 16-20 samples were taken during the reaction time, and quenched with hydrochloric acid before HPLC analysis. NIR spectra were simultaneously collected directly in the reaction mixture, even when precipitated material was present in the reactor.

The total amount of overalkylated substances in each sample was determined by HPLC. The overalkylated substances are a number of compounds formed by reaction with more than one equivalent of alkylating agent, and may contain more than two aromatic rings. The overalkylated substances have longer retention times than iodixanol itself on reversed phase HPLC columns. The results of the HPLC analyses are summarized in Table 1. Note that the sample times are different in each experiment.

Table 1. HPLC results

Experiment no.	1	2	3
Sample no.	Overalkylated substances (area %)	Overalkylated substances (area %)	Overalkylated substances (area %)
1	1.9	0.751	0.717
2	1.8	0.939	0.741
3	1.8	1.161	0.760
4	1.7	1.165	0.780
5	1.8	1.217	0.753
6	1.8	1.386	0.803
7	1.7	1.393	0.818
8	1.5	1.401	0.831
9	1.6	1.462	0.860
10	1.6	1.487	0.842
11	1.6	1.397	0.859
12	1.6	1.405	1.165
13	1.6	1.512	1.127
14	1.6	1.527	1.166
15	1.6	1.509	1.178
16	1.6	1.703	1.210
17	1.6	-	1.200
18	1.6	-	1.217
19	-	-	1.220
20	-	-	1.256

A calibration model was built up from the sample data given in Table 1 using Unscrambler II (version 5.0), a program available from Camo (Computer-Aided Modelling A/S), Trondheim. The aim of the model was to predict the content of overalkylated substances in the reaction mixtures from the corresponding NIR spectra. The raw spectra from the NIR analyzer were pretreated before

being used to build the model. The preferred pretreatment of the spectra is the following:

1. Dividing by the reference spectrum of air
2. Converting from transfectance to absorbance by $\log(1/x)$
3. Area normalization to compensate for differences in absorption caused by turbid solution

Figure 1 and Figure 2 of the accompanying drawings show an example of NIR spectrum before (Figure 1) and after (Figure 2) pretreatment as described above.

Separate calibration models for each of the three experiments were made after pretreatment of the spectra as indicated above. Subsequently, the results of all the experiments were combined into one model. The different parts of each spectrum are given different weight in the calibration model, i.e. different regression coefficients. A graphical plot of the weighing in the combined model is shown in Figure 3 of the accompanying drawings. A summary of the calibration results is given in Table 2.

Table 2. Calibration results. Y in the table represents the content of overalkylated substances in the samples (area %)

Experiment	% of Y explained	Correlation	Standard error of prediction	Slope of regression line
1	80.4	0.820	0.063	0.746
2	87.4	0.901	0.082	0.846
3	97.7	0.977	0.044	0.934
Combined	93.1	0.953	0.105	0.918

The figures in Table 2 indicate that, e.g., 97.7 % of the variation of Y (content of overalkylated substances) can be explained by the calibration model for experiment 3. In total, the combined calibration model is able to explain 93.1 % of the Y variation. The correlation between the input values (reference values determined by HPLC) and the output values (the corresponding values predicted by the model) is 0.918. A perfect correlation would be 1.000, which would mean that a perfect linearity between the NIR spectra and the Y values was observed for all the reference data.

A graphical presentation of the results from the combined model is given in Figure 4 of the accompanying drawings. This is a plot of area % values for overalkylated substances as predicted (from the NIR spectra) by the combined model compared with the values determined by HPLC.

The models mentioned above were built using all the samples. To check the predictive value of the model, the data was randomly split into calibration samples and prediction samples. Three samples from experiments 1 and 2 and four samples from experiment 3, in addition to nine other samples from the combined data, were picked out to be used as prediction samples, while a calibration model was built upon the rest of the samples. This comparison of predicted and measured values gave the following results, set out in Table 3:

Table 3. Predicted and measured values of content of overalkylated substances (area %).

Experiment	Prediction sample	Measured value	Predicted value	Deviation
1	1-5	1.8	1.704	0.054
	1-9	1.6	1.589	0.043
	1-17	1.6	1.627	0.051
2	2-6	1.386	1.407	0.121
	2-13	1.512	1.522	0.057
	2-15	1.509	1.562	0.062
3	3-3	0.760	0.740	0.043
	3-9	0.860	0.811	0.036
	3-14	1.166	1.200	0.019
	3-19	1.220	1.204	0.031
Combined	1-3	1.8	1.702	0.081
	1-8	1.5	1.629	0.077
	1-13	1.6	1.681	0.048
	2-2	0.939	1.108	0.109
	2-3	1.161	1.133	0.087
	2-7	1.393	1.438	0.067
	3-2	0.741	0.725	0.056
	3-7	0.818	0.793	0.068
	3-16	1.210	1.197	0.048

The data set out in Table 3 is also presented graphically in Figure 5 of the accompanying drawings.

Necessary actions during the synthesis are taken based on the content of overalkylated substances in the reaction mixture. Such actions may be, e.g. termination of the reaction by addition of hydrochloric acid when a content of overalkylated substances of 1.4 % or more is detected, or alternatively addition of small amounts of

hydrochloric acid to decrease pH if the content of overalkylated substances is determined to more than 0.7 % after 22 hours of reaction. The calculations reviewed in this example show that HPLC analyses can be replaced by on-line NIR analyses to determine the content of overalkylated substances sufficiently accurate for the appropriate time for the necessary actions to be taken to be identified with minimal delay.

EXAMPLE 2

Monitoring of rinse water and effluent from process equipment used in the production of iodinated X-ray contrast agents

Solutions of iohexol with concentrations of 0.00 (distilled water), 0.25, 0.45, 0.9, 1.80 and 18.0 mg iodine/mL were prepared. Raman spectra of the samples were recorded on a Labram Raman spectrometer (Dilor, France) with an acquisition time of 300 seconds and a laser power of 40 mW (Ar laser, 514.5 nm wavelength). Spectral data comprising a very intense Raman band at ca. 170 cm^{-1} , which is characteristic of tri-iodinated, aromatic rings, were fed into a multivariate calibration software and the detection limit (DL) of iohexol in water was estimated from the standard error of prediction determined from a plot of predicted versus known concentration values. A standard error of prediction of 0.45 mgI/mL was obtained which yields a DL of approximately 1 mg I/mL, which is equivalent to approximately 2 mg iohexol/ml (ppm).

This shows that Raman spectrometry is able to follow the concentration of iodinated X-ray media in water down to low ppm levels and that it can be used in on-line monitoring of rinse water and effluents following the cleaning of process equipment after termination of the process cycle.

Claims:

1. A process for the production of an organic iodinated X-ray contrast agent, characterized in that process control comprises vibrational spectroscopic monitoring of the reaction mixture in at least one of the process steps.
2. A process as claimed in claim 1 wherein said spectroscopic monitoring comprises near-infrared spectroscopic monitoring.
3. A process as claimed in claim 1 wherein said spectroscopic monitoring comprises Raman spectroscopic monitoring.
4. A process as claimed in claim 1 wherein said spectroscopic monitoring comprises infrared spectroscopic monitoring.
5. A process as claimed in any one of claims 1 to 4 wherein said reaction mixture is aqueous.
6. A process as claimed in claim 5 wherein said reaction mixture is an aqueous solution.
7. A process as claimed in any one of claims 1 to 5 wherein process parameters are adjusted following an automated comparison of data deriving from detected vibrational spectra with predetermined calibration data.
8. A process as claimed in claim 7 wherein said calibration data are derived from multivariate analysis of vibrational spectra of a set of calibration samples.
9. A process as claimed in any one of claims 1 to 8 wherein said spectroscopic monitoring involves in-situ measurement of vibrational spectra in a reaction vessel

or a duct connecting reaction vessels.

10. A process as claimed in any one of claims 1 to 8 wherein said spectroscopic monitoring involves on-line sampling of said reaction mixture from a reaction vessel or a duct connecting reaction vessels and measurement of vibrational spectra of samples thus drawn from said vessel or duct.

11. A process as claimed in any one of claims 1 to 10 wherein said vibrational spectroscopic monitoring involves monitoring physical characteristics of a solid product.


12. A process as claimed in claim 11 wherein said vibrational spectroscopic monitoring involves monitoring the crystalline type of a solid product.

13. A process as claimed in any one of the preceding claims wherein said X-ray contrast agent is a non-ionic X-ray contrast agent.

14. A process as claimed in any one of the preceding claims wherein said X-ray contrast agent is selected from iohexol, iopentol, iodixanol, iopamidol and ioversol.


1/5


FIG. 1



2/5

FIG. 2





4/5




FIG. 4

5/5




FIG. 5

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/03205

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K49/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 686 061 A (LI CHUN ET AL) 11 November 1997 see abstract; claim 14 see column 7, line 30-35 & WO 95 27513 A ---	1-14
X	PRIEBE H ET AL: "Synthesis and characterization of iodixanol." ACTA RADIOL SUPPL, 1995, 399 P21-31, DENMARK, XP002061574 see abstract; figure 4; table 3 see page 29 --- -/-	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

9 April 1998

Date of mailing of the international search report

15.05.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

INTERNATIONAL SEARCH REPORT

Inter: .nal Application No
PCT/GB 97/03205

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FELDER E ET AL: "IOPAMIDOL" ANALYTICAL PROFILES OF DRUG SUBSTANCES, vol. 17, 1 January 1988, pages 115-154, XP000562617 see abstract see page 119 - page 121 ---	1-14
Y	EP 0 120 583 A (SUN TECH INC ;CHILDRENS HOSP MEDICAL CENTER (US)) 3 October 1984 see abstract ---	1-14
Y	US 5 191 119 A (SOVAK MILOS ET AL) 2 March 1993 see abstract ---	1-14
Y,P	WO 97 27172 A (MALLINCKRODT MEDICAL INC ;DUNN THOMAS JEFFREY (US); WHITE DAVID H) 31 July 1997 see abstract ---	1-14
Y	US 4 001 323 A (FELDER ERNST ET AL) 4 January 1977 see abstract -----	1-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 97/03205

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

Claims Nos.: 1-13

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

In view of the large number of compounds, which are defined by the general definition in the independent claims, the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims, and to the general idea underlying the application (see Guidelines, Part B, Chapter III, paragraph 3.6).

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 97/03205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5686061 A	11-11-97	AU 2380095 A WO 9527513 A	30-10-95 19-10-95
EP 0120583 A	03-10-84	BE 899028 A CA 1226521 A CH 664492 A DE 3406834 A DK 107284 A FI 840534 A,B FR 2541580 A GB 2135578 A,B JP 1777654 C JP 4068290 B JP 59216827 A NL 8400542 A SE 466187 B SE 8401030 A US 4640833 A	28-08-84 08-09-87 15-03-88 30-08-84 29-08-84 29-08-84 31-08-84 05-09-84 28-07-93 02-11-92 06-12-84 17-09-84 13-01-92 29-08-84 03-02-87
US 5191119 A	02-03-93	US 4584401 A AU 3550584 A EP 0160036 A JP 61500549 T WO 8501727 A	22-04-86 07-05-85 06-11-85 27-03-86 25-04-85
WO 9727172 A	31-07-97	AU 1708197 A	20-08-97
US 4001323 A	04-01-77	CH 608189 A AR 211853 A AT 349449 B AT 349450 B AT 340582 B AT 342579 B AU 475785 B AU 8751675 A BE 836355 A BG 26512 A CA 1046082 A CS 194234 B DD 122475 A	29-12-78 31-03-78 10-04-79 10-04-79 27-12-77 10-04-78 02-09-76 02-09-76 08-06-76 12-04-79 09-01-79 30-11-79 12-10-76

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/03205

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4001323 A		DE 2547789 A	24-06-76
		DK 567475 A,B,	14-06-76
		FR 2293919 A	09-07-76
		GB 1472050 A	27-04-77
		IN 142089 A	28-05-77
		JP 1097667 C	14-05-82
		JP 51082236 A	19-07-76
		JP 56042581 B	06-10-81
		MX 3174 E	09-06-80
		NL 7512208 A,B	15-06-76
		SE 409993 B	17-09-79
		SE 7514076 A	14-06-76
		SI 7513155 A	31-12-94
		ZA 7507222 A	24-11-76
